Abiomed (ABMD) Halted Ahead of FDA Meeting on Blood Pumps
- OPEC Maintains Oil Production Target
- Market Wrap: Durable Goods Order Outpace in Oct.; GoPro's Drone Ambitions; New Home Sales Fall Flat
- Deere & Co. (DE) Tops Q4 EPS by 26c
- After-Hours Stocks Movers 11/26: (CJES) (GPRO) Higher; (KITE) (AVNR) Lower (more...)
- U.S. Durable Goods Orders Show Surprise 0.4% Gain in Oct.; Inventories Rise to Highest-Ever Level
Abiomed, Inc. (NASDAQ: ABMD) halted ahead of FDA advisory committee meeting over nonroller-type cardiopulmonary bypass blood pumps.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abiomed to Present at the Piper Jaffray 26th Annual Healthcare Conference
- Bristol-Myers Squibb (BMY) Receives Complete Response Letter from FDA for Daclatasvir NDA
- Mylan (MYL) Affirms Baxter (BAX) Suit Over Generic BREVIBLOC ANDA Filing
Create E-mail Alert Related CategoriesFDA, Trading Halts
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!